An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis - Atlantic Healthcare

HEALTHCARE PRACTITIONERS
CONTACT US

About
Research
Therapeutic Focus
- Crohn’s Disease
- Ulcerative colitis
Pipeline
Investors
News
- Conferences

Search

HEALTHCARE PRACTITIONERS
CONTACT US

P. Miner JR, M. Wedel, B. Bane & J. Bradley

Aliment Pharmacol Ther (2004) 19: 281-286

Recent Posts

Atlantic Healthcare supports World IBD Day
19th May 2020
Atlantic Healthcare appoints finance industry veteran Andrew Jones to Board of Directors
19th February 2020
Atlantic Healthcare Hosts Key Opinion Leader Discussion on Unmet Medical Need in Ulcerative Colitis and the Advantages of Alicaforsen
31st January 2020
Atlantic Healthcare to present at JPM / Biotech Showcase 13-15 January 2020, San Francisco, USA
17th December 2019
Atlantic Healthcare Announces Results from Phase 3 Trial of Alicaforsen Enema for Orphan-Designated Pouchitis
31st July 2019

Follow

Privacy Preference Center

Privacy Preferences